Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | YAP1 | P46937 | 1/20 | 0.61 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477863 | 0.87 | KMT2A (0.70) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL3303527 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL3971438 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL8200466 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL4537086 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL699639 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL10724066 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL565301 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL8203532 | 0.86 | PKM (0.88) | KMT2APKMALDH1A1LMNAPOLB | |
| SCHEMBL6744239 | 0.84 | ALDH1A1 (0.71) | KMT2APKMALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | claimed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | claimed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| CN-116606292-A | Pyrido [1,2-a ] pyrimidinone derivatives containing sulfonamide unit, preparation method and application thereof | 贵州大学 | 2023-08-18 | — | — | CN | disclosed |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | disclosed |
| US-6696418-B1 | ANIMAL GROWTH REGULATORS SUCH AS 6-AMINO-2-(2-((1-BENZENE SULFONYL-PIPERIDINE-4-CARBONYL)-AMINO)-3-(1H-INDOL-3-YL)-PROPIONYLAMINO) -HEXANOIC ACID TERT-BUTYL ESTER, ADMINISTERED TO MODULATE CELL DIFFERENTIATION | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | KMT2A 2405/4885PKM 3655/4885ALDH1A1 3407/4885 |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | KMT2A 2464/4885PKM 3663/4885ALDH1A1 3284/4885 |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | KMT2A 2464/4885PKM 3663/4885ALDH1A1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.